(Fezakinumab)Biosimilar Reference Antibody-GS40264

货号：GS40264

Fezakinumab (development code ILV-094) is an investigational, fully human monoclonal IgG1 antibody developed for the treatment of inflammatory and autoimmune diseases, particularly rheumatoid arthritis (RA) and psoriasis. It functions as a selective interleukin-22 (IL-22) inhibitor. By binding with high affinity to IL-22 in the circulation, fezakinumab prevents the cytokine from interacting with its receptor complex, IL-22R1 and IL-10R2, which is expressed on epithelial cells and certain immune cells in tissues such as the skin and joints. This blockade inhibits the downstream pro-inflammatory and tissue-remodeling signals driven by IL-22, aiming to reduce inflammation, hyperproliferation, and tissue damage characteristic of these diseases.